What are the barriers to treating spinal cord injury?
That is the subject of a live video chat from the journal Science Translational Medicine. The chat will take place Thursday October 24 at 3 pm EDT. Special guests will be neurosurgeon Michael Fehlings
, chair in neural repair and regeneration at the University Health Network in Toronto, Canada, and research scientist Martin Schwab
, co-director of the Brain Research Institute at the University of Zurich in Switzerland. [tp:readmore]
To access the video feed, go to this page
; a video box will appear before the chat begins.
Says the journal, “We will discuss the many barriers to treating spinal cord injury and will take your questions.” The video feed will feature a comment box.
Both Fehlings and Schwab are active in Reeve Foundation research activities. Fehlings is Principal Investigator for a Phase II clinical trial of the drug riluzole for acute SCI, sponsored in part by the North American Clinical Trials Network, a Reeve initiative.
Schwab heads a lab in Zurich that is part of the seven-member International Research Consortium on Spinal Cord Injury
, sponsored by the Reeve Foundation.
From Science Magazine's Facebook page
VIDEO CHAT: Treating Spinal Cord Injury
THURS 10/24 3pm EDT!
In the United States, more than 10,000 people sustain spinal cord injuries each year. There are currently many experimental therapies to treat paralysis, but how soon can we move them from the lab to the clinic? Find out this THURS 10/24 at 3pm EDT in a LIVE G+ Hangout with neurosurgeon Michael Fehling and neuroscientist Martin Schwab.
Leave questions at: http://scim.ag/1a7Lduc
[Image Credit: Wikimedia Commons/©Bruce Blaus]